ArticleCell cycle (Georgetown, Tex.)2016

STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.

Elisabet Cuyàs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.